| Scott Thomas Palasik, PHD, CCC-SLP | |
|
School Of Speech-language Pathology & Audiology, The Polsky Building, Rm. 181, Akron, OH 44325-3001 | |
| (330) 972-8185 | |
| Not Available |
| Full Name | Scott Thomas Palasik |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | School Of Speech-language Pathology & Audiology, Akron, Ohio |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811240575 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 8941 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Scott Thomas Palasik, PHD, CCC-SLP School Of Speech-language Pathology & Audiology, The Polsky Building, Rm. 181, Akron, OH 44325-3001 Ph: (330) 972-8185 | Scott Thomas Palasik, PHD, CCC-SLP School Of Speech-language Pathology & Audiology, The Polsky Building, Rm. 181, Akron, OH 44325-3001 Ph: (330) 972-8185 |
News Archive
Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose "Quad" regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.
Research to be presented this week at The Federation of American Societies for Experimental Biology Conference in Washington, D.C., demonstrates that consumption of white potatoes by children does not displace other vegetables from children's meals.
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).
A multi-institutional team of investigators led by bioengineer Ankur Singh has developed research tools that shed new light on a virtually untreatable form of prostate cancer, opening a pathway that may lead to novel therapeutics and a glimmer of hope for patients.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for its review of the New Drug Application (NDA) for Fampridine-SR to January 22, 2010. The original Prescription Drug User Fee Act (PDUFA) date for this priority review application was October 22, 2009.
› Verified 7 days ago
Michele Y Gunther, S.P.L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Jamie Blaylock, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 450 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-376-0153 | |
Kimberly Marie Gibbons, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2425 Foxboro Ave, Akron, OH 44305 Phone: 330-631-5678 | |
Kristin Weaver, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Mrs. Elizabeth Kinzig, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Wyant Rd, Akron, OH 44313 Phone: 330-836-7953 | |
Mrs. Andrea P. Brewer, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 181 Polsky Building, Akron, OH 44325 Phone: 330-972-8189 Fax: 330-972-7884 | |
Mary Mariani-walker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1199 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-873-3396 |